Unknown

Dataset Information

0

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity.


ABSTRACT: Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the many unanswered questions that remain regarding LAG-3 biology. Of these, we address: (i) the function of the many LAG-3-ligand interactions, (ii) the hurdles that remain to acquire a high-resolution structure of LAG-3, (iii) the under-studied LAG-3 signal transduction mechanism, (iv) the elusive soluble form of LAG-3, (v) the implications of the lack of (significant) phenotype of LAG-3 knockout mice, (vi) the reports of LAG-3 expression on the epithelium, and (vii) the conflicting reports of LAG-3 expression (and potential contributions to pathology) in the brain. These mysteries which surround LAG-3 highlight how the ever-evolving study of its biology continues to reveal ever-increasing complexity in its role as an immune receptor. Importantly, answering the questions which shroud LAG-3 in mystery will allow the maximum therapeutic benefit of LAG-3 targeting immunotherapies in cancer, autoimmunity and beyond.

SUBMITTER: Burnell SEA 

PROVIDER: S-EPMC8895726 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature

altmetric image

Publications

Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity.

Burnell Stephanie E A SEA   Capitani Lorenzo L   MacLachlan Bruce J BJ   Mason Georgina H GH   Gallimore Awen M AM   Godkin Andrew A  

Immunotherapy advances 20211220 1


Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the many unanswered questions that remain regarding LAG-3 biology. Of these, we address: (i) the function of the many LAG-3-ligand inter  ...[more]

Similar Datasets

| S-EPMC10807162 | biostudies-literature
| S-EPMC11501932 | biostudies-literature
| S-EPMC7073516 | biostudies-literature
| S-EPMC7883684 | biostudies-literature
| S-EPMC4261025 | biostudies-literature
| S-EPMC10328263 | biostudies-literature
| S-EPMC6282070 | biostudies-literature
| S-EPMC7293705 | biostudies-literature
| S-EPMC3467740 | biostudies-literature
| S-EPMC10525260 | biostudies-literature